Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species

Gynecologic Oncology

Volumn 137, Issue 2, 2015, Pages 299-305

  Mizuno, T ^a   Suzuki, N ^a   Makino, H ^a   Furui, T ^a   Morii, E ^b   Aoki, H ^c   Kunisada, T ^c   Yano, M ^d   Kuji, S ^e   Hirashima, Y ^e   Arakawa, A ^f   Nishio, S ^g   Ushijima, K ^g   Ito, K ^h   Itani, Y ⁱ   Morishige, K ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c GIFU UNIVERSITY   (Japan)

^d OITA UNIVERSITY   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

^f NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KANSAI ROSAI HOSPITAL   (Japan)

ⁱ Shichijo Nishimachi   (Japan)

Author keywords

Aldehyde dehydrogenase; Cancer stem like cell; Chemoresistance; Nrf2 antioxidant pathway; Ovarian clear cell carcinoma; Reactive oxygen species

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD133 ANTIGEN; GLUTATHIONE PEROXIDASE 3; HEME OXYGENASE 1; HERMES ANTIGEN; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; ISOENZYME; RETINAL DEHYDROGENASE;

ADENOCARCINOMA CELL LINE; ADULT; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CELL LEVEL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; EARLY CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA; AGED; CANCER STEM CELL; ENZYMOLOGY; METABOLISM; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PROGNOSIS; REACTIVE OXYGEN SPECIES; RETINAL DEHYDROGENASE;

EID: 84933279818     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.12.005     Document Type: Article

References (32)

1. Bast Jr RC, Hennesy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
2. Goff BA, Sainz De La Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996;60: 412-7.
3. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000;88:2584-9.
4. Utsunomiya H, Akahira J, Tanno S, Moriya T, Toyoshima M, Niikura H, et al. Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 2006;16:52-5.
5. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells fromprimary human tumors. Cancer Res 2008;68:4311-20.
6. Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell 2007;1:485-7.
7. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cell (SC) and tracks SC overexpression during colon tumorigenesis. Cancer Res 2009;69:3382-9.
8. Dembinski JL, Krauss S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis 2009;26:611-23.
9. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-56.
10. Landen Jr CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, et al. Targeting aldehyde dehydrogenase cancer stemcells in ovarian cancer. Mol Cancer Ther 2010;9: 3186-99.
11. Liu S, Liu C, Min X, Ji Y, Wang N, Liu D, et al. Prognostic value of cancer stem cell marker aldehyde dehydrogenase in ovarian cancer: a meta-analysis. PLoS One 2013;8:e81050.
12. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cell. Nature 2009;458:780-3.
13. Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW, et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer 2011;129:820-31.
14. Kim HM, Haraguchi N, Ishii H, Ohkuma M, Okano M, Mimori K, et al. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Ann Surg Oncol 2012;19:539-48.
15. Hara H, Adachi T. Contribution of hepatocyte nuclear factor-4 to down-regulation of CYP2D6 gene expression by nitric oxide. Mol Pharmacol 2002;61:194-200.
16. Konstantinopolus PA, Spentzos D, Fountzilas E, et al. Keap1 mutations and 'Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 2011;71:5081-9.
17. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010;5:e10277.
18. Wang YC, Yo YT, Lee HY, Liao YP, Chao TK, Su PH, et al. ALDH1-bright epithelial ovarian cancer cells are associated with CD44 expression, drug resistance, and poor clinical outcome. Am J Pathol 2012;180:1159-69.
19. Kuroda T, Hirohashi Y, Torigoe T, Yasuda K, Takahashi A, Asanuma H, et al. ALDH1-high ovarian cancer stem-like cells can be isolated from serous and clear cell adenocarcinoma cells, and ALDH1 high expression is associated with poor prognosis. PLoS One 2014;8:e65158.
20. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 2009;22:817-23.
21. Ricci F, Bemasconi S, Porcu L, Erba E, Panini N, Fruscio R, et al. ALDH enzyme activity and CD133 positivity and response to chemotherapy in ovarian cancer patients. Am J Cancer Res 2013;3:221-9.
22. Buyse ME, Squifflet P, Laporte S, et al. Prediction of survival in patients with advanced non small cell lung cancer: evidence froma pooled analysis of 2,838 patients randomized in 7 trials. J Clin Oncol 2008;26:8019.
23. Buyse ME, Burzykowski T, Carroll K, Michiels S, Pignon JP, Piedbois P, Meta-Analysis Group in Cancer (MAGIC). Progression-free survival (PFS) as a surrogate for survival in patients with advanced colorectal cancer: an analysis of 3159 patients randomized in 11 trials. J Clin Oncol 2005;23:3513.
24. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;101:1642-9.
25. Tiligada E. Chemotherapy: induction of stress responses. Endocr Relat Cancer 2006; 13:115-24.
26. Landriscina M, Maddalena F, Laudiero G, Esposite F. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal 2009;11:2701-16.
27. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004;10:549-57.
28. Zhou S, Ye W, Shao Q, Zhang M, Liang J. Nrf2 is a potential therapeutic target in radioresistance in human cancer. Crit Rev Oncol Hematol 2013;88:706-15.
29. Yeung B, Wong KY, Lin MC, Wong CK, Mashima T, Tsuruo T, et al. Chemosensitisation by manganese superoxide dismutase inhibition is caspase-9 dependent and involves extracellular signal-regulated kinase 1/2. Br J Cancer 2008;99: 283-93.
30. Saga Y, Ohwada M, Suzuki M, Konno R, Kigawa J, Ueno S, et al. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell carcinoma. Oncol Rep 2008;20:1299-303.
31. Landriscina M, Maddalena F, Laudiero G, Esposito F. Adaptation to oxidative stress, chemoresistance, and cell survival. Antioxid Redox Signal 2009;11:2701-16.
32. Galic V, Coleman RL, heizog TJ. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways. Curr Cancer Drug Targets 2013; 13:698-707.